Check Out the Startups Participating In Our Most Recent Lifetech Batch

Lifetech
Plug and Play connects leading corporations, universities, and economic development organizations with innovative life sciences startups, driving the future of the lifetech industry.
Through our global Lifetech accelerator, organizations gain early access to breakthrough technologies, validate solutions through pilots and partnerships, and accelerate innovation across biological research, biotechnology, and healthcare. At PNP, we help industry leaders discover, partner with, and invest in the startups shaping the future of life sciences.
Areas of Expertise
The use of data science, AI, and bioinformatics to analyze biological data and improve healthcare. Organizations that learn to interpret bioinformatics and act on it at scale have a structural advantage over those that do not.
On the other hand, efficient biomanufacturing is the difference between a technology that works in the lab and one that can reach the market.

The use of data science, AI, and bioinformatics to analyze biological data and improve healthcare. Organizations that learn to interpret bioinformatics and act on it at scale have a structural advantage over those that do not.
On the other hand, efficient biomanufacturing is the difference between a technology that works in the lab and one that can reach the market.

Solutions that address disparities in healthcare access and improve health equity for all populations.

Innovative medical devices, diagnostic tools, and technologies for improved patient outcomes.

Regenerative medicine and cell therapies are opening new treatment avenues for diseases that, until recently, had no viable therapeutic options. For corporations operating in this space, the challenge is to find technology mature enough to pilot, with teams capable of execution and a clear path to commercial scalability.
That is exactly what Lifetech’s selection process ensures before a startup reaches a partner’s desk.

Corporations working in this area need to shorten development cycles, reduce the risk of R&D programs, and access technology platforms that multiply their discovery capacity without increasing their internal costs.
Through the Lifetech life sciences accelerator, we connect organizations with startups that apply artificial intelligence, genomic analysis, and new discovery platforms to accelerate therapeutic development.

Late diagnosis imposes additional costs on healthcare systems, insurers, and corporations that develop or distribute medical technology. Organizations operating in this area seek technology that improves accuracy, reduces diagnosis time, and enables more predictive and personalized medicine.
We connect our partners with life science startups in precision diagnostics, connected medical devices, advanced imaging tools, and predictive medicine, providing direct access to IU Health for validation in a real-world clinical setting.


“We have the perfect partner: Plug and Play. Fantastic organization, great history, proven track record, lots of integrity, but most importantly, the ambition and the sense of urgency that we feel as well at Indiana University. We really want to use the Plug and Play brand and the partnership to be known as one of the most innovative universities in this space.”
— Pamela Whitten, President, Indiana University
Internal R&D cycles in life sciences can take years, but we help shorten that cycle. Through the Lifetech program, organizations gain access to pre-screened startups and run structured pilots to rapidly validate new technology. This creates an active innovation pipeline that moves faster than traditional internal R&D, allowing you to bring solutions to market more quickly.
In life sciences, being first to a technology is a competitive advantage. The Lifetech program gives its partners early access to the most advanced life sciences startups on the market before they gain public visibility. Organizations participating in the program anticipate innovation rather than reacting to it.
Organizations that work with us do not explore the market blindly and gain access to technology that has already been evaluated against real-world use cases in the life sciences sector, and to a life sciences venture capital network that can support the most promising ones from pilot to commercial scale.
We identify high-priority opportunities across the life sciences landscape, including adopting new platforms, optimizing processes, or integrating advanced diagnostic tools.
Using our database of 100K+ startups, we match partners with startups aligned with their strategic goals, technical requirements, and use cases in life sciences innovation.
We enable structured startup pilots that accelerate proof-of-concept for specific use cases and technologies to help validate technology in weeks, not quarters.
After a successful pilot, we continue supporting our partners in converting initial startup engagement into long-term commercial partnerships & investment opportunities.
Our partners gain exclusive access to industry-specific events and high-level collaboration opportunities curated for their interests throughout the program.
Our programs conclude with an Expo or Summit, where selected startups present validated technologies to a broader audience of executives, investors, and industry leaders.
“The IU LAB is proud to partner with Plug and Play, Central Indiana Corporate Partnership, and IU Health to help grow Indiana’s innovation economy. This partnership reflects our commitment to translating IU’s $1B research enterprise, attracting and developing world-class talent, and building the next generation of companies right here in Indiana. Together, we’re strengthening the state’s position as a national hub for life sciences and groundbreaking innovation.”
— David Rosenberg, President & CEO, IU LAB


PNP works with leading corporations in the sector to help them discover, test, and invest in emerging technology in a structured, privileged-access way.
Together, we define your innovation priorities, select startups from our global network that address your specific use cases, and organize the validation process so your team can achieve results in weeks.
What you get is an active pipeline managed by a team with over twenty years of experience connecting corporations that combines startup scouting, technology validation, and life sciences venture capital access.
PNP collaborates with universities and economic development corporations (EDCs) to turn scientific knowledge into viable companies, connect research talent with private capital, and build life sciences innovation ecosystems that generate high-value jobs and attract long-term investment.
The model we developed with Indiana University and the IU LAB is the benchmark: co-design of the program, shared access to research infrastructure, and a collaboration that has positioned the university as a global leader in life sciences innovation.
For EDCs, collaborating with Lifetech is a direct way to strengthen the local life sciences ecosystem and connect it to PNP’s global network.


If you are an early-stage startup with solid life sciences technology, the Lifetech program is your direct gateway to corporations, investors, and healthcare systems that can bring your technology to market.
We work with each organization to identify its innovation priorities and select startups from our global network that address its specific use cases. Corporations participating in the Lifetech program have access to a structured process that spans from technology identification to pilot validation and commercial investment. This is not just generic access to the startup market, but a life sciences innovation pipeline that combines startup scouting, technology validation, and access to life sciences venture capital, all tailored to our partners’ specific objectives.
The program works with:
The most comprehensive collaboration model is the one we have developed with Indiana University and the IU LAB: Joint program design, shared access to research infrastructure, and a partnership that transforms the academic ecosystem into a direct asset for accelerating life sciences startups. For governments and public agencies, the collaboration is geared toward building innovation ecosystems that generate high-value jobs, attract private investment, and position the region as a global leader in life sciences.
The program operates out of the 16 Tech Innovation District in Indianapolis, Indiana, in collaboration with the IU LAB. Indianapolis is one of the most active life sciences ecosystems in the United States, with companies like Eli Lilly and Zimmer Biomet as part of the city’s industrial fabric. That said, access to the program is not geographically limited, and Batch 1 brought together startups from eight U.S. states and three countries.
Partners joining the Lifetech program have access to three main mechanisms. First, access to the top-tier life sciences startups in our global network. Second, participation in Selection Days, our structured sessions where corporations directly evaluate the startups in the batch and initiate pilot or collaboration discussions. Third, through one-on-one meetings with founders selected based on your technical and strategic priorities. The process is designed so that your team can engage in meaningful conversations as quickly as possible.
Lifetech is the Plug and Play program specifically dedicated to innovation in life sciences. Other programs focus on different verticals such as Fintech, Mobility, Sustainability, or Brand & Retail. What makes Lifetech unique within our ecosystem is the combination of scientific focus, access to the best-in-class startups in lifetech and real-world healthcare systems through IU Health, and the network of corporations specialized in the sector.
Check Out the Startups Participating In Our Most Recent Lifetech Batch
Bahto Biosciences develops non-opioid small-molecule therapeutics for painful peripheral neuropathy, a condition with limited effective treatment options that afflicts more than 19 million Americans.
Cryton Biosciences is developing a first-in-class dual-action drug that restores mitochondrial function in immune AND cancer cells resulting in tumor death.
Novel Therapies for Cardiovascular and Metabolic Diseases
Humimic Biosystems provides organ-on-chip models for human-relevant preclinical research and drug testing.
NEXI Biotech develops in vitro neurotechnology models for improved neurological drug discovery and translation.
Sabiad offers integrated diagnostic and therapeutic solutions for precise bacterial infection management.
Terra Bioforge engineers overproduction of microbial-based natural product compounds with billion-dollar end markets.
Transforming Drug Discovery with models that reflect human physiology.
Head Diagnostics offers AI-driven digital tools for cognitive and neurological assessment.
Levisonics is developing a drop-of-blood, point-of-care coagulation analyzer that delivers in a single test the comprehensive clotting insights that today require multiple separate lab and point-of-care tests.
Founded by an Ex-NASA engineer and two gastroenterologists, Edulis is building the first drug delivery system for sustained, localized treatment of chronic GI diseases like IBD and colorectal cancer.
The vendor-neutral coordination and translation layer for biomanufacturing data, connecting pharma sponsors and their manufacturing partners so AI can finally scale and deliver real value.

Karlens Joas and Angie Chan

Laura Soto

Polina Stavrovski

We have a community of experts all over the world. We work as a bridge between Silicon Valley and the rest of the world, making innovation open to anyone, anywhere.